Defibrotide Dose-escalation for SOS Post-HSCT

Summary

This research study is being done to determine the safety and tolerability of increasing doses of defibrotide within a single patient with sinusoidal obstructive syndrome (SOS)/veno-occlusive disease (VOD) after hematopoietic cell transplantation (HCT) associated with either kidney and/or lung impairment that has not obtained a complete response (CR) or progressed in severity with standard doses of defibrotide.

Timeline

Start

2024-03-20

Primary completion

2027-08-01

Completion

2028-08-01

Drugs

Indications